Breakthrough drug discovery research for multiple sclerosis and Alzheimer’s disease
Summary
The destruction of myelin, a protective insulation surrounding nerve axons, is the key cause of the nerve damage that underlies the accumulation of disability in people with multiple sclerosis (MS), and has recently been proposed as an early contributor to Alzheimer’s disease. Both diseases affect millions of people worldwide and are associated with enormous societal and economic costs.
An existing drug may provide a fast-track solution. In preclinical studies of multiple sclerosis nalfurafine was shown to induce remyelination and reverse paralysis when compared to placebo. Already proven to be safe for humans, a Phase 2 study of nalfurafine in people with multiple sclerosis is ready to proceed, with ethics and regulatory approvals in hand.
We seek initial funding to enable the team to explore the effects of nalfurafine in preclinical models of Alzheimer’s disease and if promising, will seek further funding to undertake a proof-of-concept clinical trial in people with Alzheimer’s disease.
Endorsed by
The scientists at Rekover Therapeutics possess extensive expertise in neuroscience, immunology and the study of demyelinating diseases. They are a dedicated and talented team that has developed a substantial, high quality preclinical data package supporting the use of nalfurafine for treating patients with multiple sclerosis.
With exciting new science reporting a strong relationship between myelin dysfunction and the development of amyloid beta plaque deposition, I am very confident in their ability to explore the utility of nalfurafine in targeting underlying myelin-related pathology associated with Alzheimer's disease.
